Genetic Engineering of T Cells for Adoptive Immunotherapy

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 2008 Oct 9

PMID 18841331

Citations 34

Authors

Angel Varela-Rohena

Carmine Carpenito

Elena E Perez

Max Richardson

Richard V Parry

Michael Milone

John Scholler

Xueli Hao

Angela Mexas

Richard G Carroll

Carl H June

James L Riley

Affiliations

Soon will be listed here.

Abstract

To be effective for the treatment of cancer and infectious diseases, T cell adoptive immunotherapy requires large numbers of cells with abundant proliferative reserves and intact effector functions. We are achieving these goals using a gene therapy strategy wherein the desired characteristics are introduced into a starting cell population, primarily by high efficiency lentiviral vector-mediated transduction. Modified cells are then expanded using ex vivo expansion protocols designed to minimally alter the desired cellular phenotype. In this article, we focus on strategies to (1) dissect the signals controlling T cell proliferation; (2) render CD4 T cells resistant to HIV-1 infection; and (3) redirect CD8 T cell antigen specificity.

Citing Articles

High-throughput discovery of MHC class I- and II-restricted T cell epitopes using synthetic cellular circuits.

Kohlgruber A, Dezfulian M, Sie B, Wang C, Kula T, Laserson U Nat Biotechnol. 2024; .

PMID: 38956325 DOI: 10.1038/s41587-024-02248-6.

Recruiting In Vitro Transcribed mRNA against Cancer Immunotherapy: A Contemporary Appraisal of the Current Landscape.

Miliotou A, Georgiou-Siafis S, Ntenti C, Pappas I, Papadopoulou L Curr Issues Mol Biol. 2023; 45(11):9181-9214.

PMID: 37998753 PMC: 10670245. DOI: 10.3390/cimb45110576.

Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.

Yoo H, Harapan B Immunol Res. 2021; 69(6):471-486.

PMID: 34554405 PMC: 8580929. DOI: 10.1007/s12026-021-09236-x.

A narrative review of chimeric antigen receptor-T (CAR-T) cell therapy for lung cancer.

Liu Y, He Y Ann Transl Med. 2021; 9(9):808.

PMID: 34268421 PMC: 8246176. DOI: 10.21037/atm-20-5419.

Surface Functionalization with Polyethylene Glycol and Polyethyleneimine Improves the Performance of Graphene-Based Materials for Safe and Efficient Intracellular Delivery by Laser-Induced Photoporation.

Liu J, Li C, Brans T, Harizaj A, Van de Steene S, Beer T Int J Mol Sci. 2020; 21(4).

PMID: 32102402 PMC: 7073198. DOI: 10.3390/ijms21041540.

References

Hassan R, Bera T, Pastan I . Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004; 10(12 Pt 1):3937-42. DOI: 10.1158/1078-0432.CCR-03-0801. View

Cooper L, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A . Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis. 2004; 33(1):83-9. DOI: 10.1016/j.bcmd.2004.03.003. View

Chemnitz J, Parry R, Nichols K, June C, Riley J . SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004; 173(2):945-54. DOI: 10.4049/jimmunol.173.2.945. View

Mitchell R, Beitzel B, Schroder A, Shinn P, Chen H, Berry C . Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2004; 2(8):E234. PMC: 509299. DOI: 10.1371/journal.pbio.0020234. View

Nadler L, Anderson K, Marti G, Bates M, Park E, Daley J . B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol. 1983; 131(1):244-50. View

Bowen D, Lane H, Fauci A . Immunopathogenesis of the acquired immunodeficiency syndrome. Ann Intern Med. 1985; 103(5):704-9. DOI: 10.7326/0003-4819-103-5-704. View

Gross G, Gorochov G, Waks T, Eshhar Z . Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc. 1989; 21(1 Pt 1):127-30. View

Vandenberghe P, Freeman G, Nadler L, Fletcher M, Kamoun M, Turka L . Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells. J Exp Med. 1992; 175(4):951-60. PMC: 2119170. DOI: 10.1084/jem.175.4.951. View

Pages F, Ragueneau M, Rottapel R, Truneh A, Nunes J, Imbert J . Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature. 1994; 369(6478):327-9. DOI: 10.1038/369327a0. View

10.

Walter E, Greenberg P, Gilbert M, Finch R, Watanabe K, Thomas E . Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995; 333(16):1038-44. DOI: 10.1056/NEJM199510193331603. View

11.

Blaese R, Culver K, Miller A, Carter C, Fleisher T, Clerici M . T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science. 1995; 270(5235):475-80. DOI: 10.1126/science.270.5235.475. View

12.

Viola A, Lanzavecchia A . T cell activation determined by T cell receptor number and tunable thresholds. Science. 1996; 273(5271):104-6. DOI: 10.1126/science.273.5271.104. View

13.

Levine B, Mosca J, Riley J, Carroll R, Vahey M, Jagodzinski L . Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science. 1996; 272(5270):1939-43. DOI: 10.1126/science.272.5270.1939. View

14.

Fremont D, Rees W, Kozono H . Biophysical studies of T-cell receptors and their ligands. Curr Opin Immunol. 1996; 8(1):93-100. DOI: 10.1016/s0952-7915(96)80111-7. View

15.

Carroll R, Riley J, Levine B, Feng Y, Kaushal S, Ritchey D . Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science. 1997; 276(5310):273-6. DOI: 10.1126/science.276.5310.273. View

16.

Wulfing C, Davis M . A receptor/cytoskeletal movement triggered by costimulation during T cell activation. Science. 1998; 282(5397):2266-9. DOI: 10.1126/science.282.5397.2266. View

17.

Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A . T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science. 1999; 283(5402):680-2. DOI: 10.1126/science.283.5402.680. View

18.

Mosier D, Picchio G, Gulizia R, Sabbe R, Poignard P, Picard L . Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol. 1999; 73(5):3544-50. PMC: 104126. DOI: 10.1128/JVI.73.5.3544-3550.1999. View

19.

Clay T, Custer M, SACHS J, Hwu P, Rosenberg S, Nishimura M . Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999; 163(1):507-13. View

20.

Riley J, June C . The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood. 2004; 105(1):13-21. DOI: 10.1182/blood-2004-04-1596. View